Raf is an Investment Manager at Korys. He joined in 2017 as an investment analyst, focusing on direct and fund investments in the life science ecosystem.
Prior to this, he spent 8 years in the European biotech sector. His career started at Eurogentec, now a part of the Kaneka corporation. Subsequently, Raf was active at Apitope, helping the company finance their drug development and out-license its compounds.
Raf holds a MSc in Biochemistry and Biotechnology from the University of Leuven (KUL) and an MBA from Vlerick Business School (Belgium).